rostafuroxin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 153976 |
| CHEMBL ID | 2068971 |
| SCHEMBL ID | 1716210 |
| MeSH ID | M0496558 |
| Synonym |
|---|
| 24-norchola-20,22-diene-3,14,17-triol, 21,23-epoxy-, (3beta,5beta,14beta)- |
| (3s,5r,8r,9s,10s,13s,14s,17s)-17-(furan-3-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,15,16-dodecahydro-1h-cyclopenta[a]phenanthrene-3,14,17-triol |
| pst-2238 |
| 21,23-epoxy-24-nor-14beta,5beta-chola-20,21-diene-3beta,14,17alpha-triol |
| unii-p848lcx62b |
| p848lcx62b , |
| rostafuroxin |
| rostafuroxin [inn] |
| 17-(3-furyl)-5beta-androstane-3,14,17-triol |
| pst 2238 |
| 156722-18-8 |
| CHEMBL2068971 |
| CS-3295 |
| HY-12283 |
| 21,23-epoxy-24-nor-14.beta.,5.beta.-chola-20,21-diene-3.beta.,14,17.alpha.-triol |
| SCHEMBL1716210 |
| AKOS025142085 |
| 3?,5?,14?)-21,23-epoxy-24-norchola-20,22-diene-3,14,17-triol |
| AC-35335 |
| rostafuroxin (pst 2238) |
| (3s,5r,8r,9s,10s,13s,14s,17s)-17-(furan-3-yl)-10,13-dimethylhexadecahydro-14h-cyclopenta[a]phenanthrene-3,14,17-triol |
| (4-{[5-chloro-4-(methylamino)-3h-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxyphenyl)(4-morpholinyl)methanone |
| J-690210 |
| EX-A192 |
| (1s,2s,5s,7r,10r,11s,14r,15s)-14-(furan-3-yl)-2,15-dimethyltetracyclo[8.7.0.0?,?.0??,??]heptadecane-5,11,14-triol |
| DB12350 |
| E4R , |
| Q1110424 |
| rostafuroxin(pst 2238) |
| rostafuroxine |
| F85054 |
| DTXSID20870040 |
Rostafuroxin is a digitoxygenin derivative that selectively displaces ouabain from the Na(+)/K(+)-ATPase receptor and lowers blood pressure in rats and humans. It is a new oral antihypertensive agent able to selectively antagonize EO, adducin pressor, and molecular effects.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rostafuroxin is a digitoxygenin derivative that selectively displaces ouabain from the Na(+)/K(+)-ATPase receptor and lowers blood pressure in rats and humans." | ( Adducin and hypertension. Bianchi, G; Staessen, JA, 2005) | 1.05 |
| "Rostafuroxin (PST 2238) is a new oral antihypertensive agent able to selectively antagonize EO, adducin pressor, and molecular effects." | ( Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Bianchi, G; Ferrandi, M; Ferrari, P; Valentini, G, 2006) | 2.5 |
| "Rostafuroxin is a new oral antihypertensive agent able to selectively antagonize adducin and EO hypertensive and molecular effects." | ( Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach. Bianchi, G; Ferrandi, M; Ferrari, P; Manunta, P; Valentini, G, 2007) | 1.06 |
| "Rostafuroxin (PST 2238) is a novel anti-hypertensive compound able to selectively antagonize EO/Ouabain and Adducin hypertensive effect and Ouabain-induced cardiac hypertrophy in rats." | ( Ouabain-dependent signaling in caveolae as a novel therapeutic target for hypertension. Bianchi, G; Ferrandi, M; Ferrari, P; Molinari, I, 2006) | 1.06 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " We propose that a pharmacogenomic approach, as applied in an ongoing Phase II dosage study of rostafuroxin, will be a critical step in moving the adducin hypothesis from experimental and observational studies to clinical application." | ( Adducin and hypertension. Bianchi, G; Staessen, JA, 2005) | 0.55 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sodium/potassium-transporting ATPase subunit alpha-1 | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0048 | 0.7807 | 6.0000 | AID146847 |
| Sodium/potassium-transporting ATPase subunit beta-1 | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0048 | 0.8134 | 6.0000 | AID146847 |
| Sodium/potassium-transporting ATPase subunit alpha-3 | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0048 | 0.8134 | 6.0000 | AID146847 |
| Sodium/potassium-transporting ATPase subunit beta-2 | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0048 | 0.8134 | 6.0000 | AID146847 |
| Sodium/potassium-transporting ATPase subunit alpha-2 | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0048 | 0.8134 | 6.0000 | AID146847 |
| Sodium/potassium-transporting ATPase subunit beta-3 | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0048 | 0.8134 | 6.0000 | AID146847 |
| Sodium/potassium-transporting ATPase subunit gamma | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0048 | 0.8134 | 6.0000 | AID146847 |
| Sodium/potassium-transporting ATPase subunit alpha-4 | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0048 | 0.8134 | 6.0000 | AID146847 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID146847 | Ability to displace [3H]ouabain from Na+/K+ ATPase in dog kidney. | 1997 | Journal of medicinal chemistry, May-23, Volume: 40, Issue:11 | 17 beta-(3-furyl)-5 beta-androstane-3 beta, 14 beta, 17 alpha-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 14 (53.85) | 29.6817 |
| 2010's | 7 (26.92) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.95) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (11.11%) | 5.53% |
| Reviews | 12 (44.44%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (44.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||